Stakeholder perspectives and preferences for long-acting injectables for tuberculosis treatment and prevention: a multi-regional mixed-methods study
- 1London School of Hygiene & Tropical Medicine
Abstract
Objective: To assess stakeholder acceptability of and preferences for long-acting injectables (LAIs) for tuberculosis (TB) treatment and prevention across World Health Organization regions to inform product development and implementation. Methods: We conducted a sequential explanatory mixed-methods study of survey data and qualitative focus group discussions (FGDs). Online surveys assessed perceptions and acceptance of LAIs among two groups: TB programme managers, civil society members and healthcare workers (Survey A), and community members and persons affected by TB (Survey B). Using purposive sampling, survey participants were invited to join FGDs to explore survey findings. Survey data were analysed using descriptive statistics, ordinal logistic regression with stepwise AIC selection, and one-sample proportion tests. FGD transcripts were analysed using modified framework analysis. Findings: Among 310 participants (102 Survey A; 208 Survey B), 83% (n=256) favoured LAIs over standard oral TB treatment. Compared with six months of daily oral treatment, 69% preferred a three-month regimen comprising one month of daily oral treatment followed by four injections per monthly visit for two months, while 80% preferred the corresponding regimen with two injections per visit. For prevention, 79% preferred a single injection over one month of oral treatment. In Survey B, interest varied according to lived TB experience, with FGDs suggesting that previous negative experiences with injectables may have contributed to this variation. Conclusion: Interest in LAIs for TB treatment and prevention was high, but lower among participants with lived TB experience. Product development and implementation should address concerns about injectables and side effects while preserving patient choice and agency.
Related
- Stakeholder perspectives on the potential introduction of a novel tuberculosis vaccine for adolescents and adults in Pakistan: A qualitative study
- Global stakeholder preferences for point-of-care HIV nucleic acid amplification tests: A conjoint study
- Knowledge, attitudes and behaviours related to tick awareness and prevention among users of urban green spaces: insights from stakeholder focus groups
- Developing and piloting a discrete choice experiment to assess stakeholder preferences for community-based exercise programmes after stroke
- Preferences for treatment for latent tuberculosis infection in primary care among people in the USA at increased risk of tuberculosis: a pilot survey.
BibTeX
@misc{kim2026stakeholder,
title = {{Stakeholder perspectives and preferences for long-acting injectables for tuberculosis treatment and prevention: a multi-regional mixed-methods study}},
author = {C. Kim and E. V. McConnell and S. G. Schumacher and D. Falzon and M. Gegia and L. Aprilawati and J. Galarza and E. Tembo and L. Tonkonoh and G. M. Knight and C. F. McQuaid and F. Mirzayev and N. West},
howpublished = {medRxiv},
year = {2026},
month = nov,
doi = {10.64898/2026.11.06.26367430},
url = {https://www.medrxiv.org/content/10.64898/2026.11.06.26367430v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Stakeholder perspectives and preferences for long-acting injectables for tuberculosis treatment and prevention: a multi-regional mixed-methods study
AU - C. Kim
AU - E. V. McConnell
AU - S. G. Schumacher
AU - D. Falzon
AU - M. Gegia
AU - L. Aprilawati
AU - J. Galarza
AU - E. Tembo
AU - L. Tonkonoh
AU - G. M. Knight
AU - C. F. McQuaid
AU - F. Mirzayev
AU - N. West
PY - 2026
DA - 2026/11/06
PB - medRxiv
DO - 10.64898/2026.11.06.26367430
UR - https://www.medrxiv.org/content/10.64898/2026.11.06.26367430v1
AB - Objective: To assess stakeholder acceptability of and preferences for long-acting injectables (LAIs) for tuberculosis (TB) treatment and prevention across World Health Organization regions to inform product development and implementation. Methods: We conducted a sequential explanatory mixed-methods study of survey data and qualitative focus group discussions (FGDs). Online surveys assessed perceptions and acceptance of LAIs among two groups: TB programme managers, civil society members and healthcare workers (Survey A), and community members and persons affected by TB (Survey B). Using purposive sampling, survey participants were invited to join FGDs to explore survey findings. Survey data were analysed using descriptive statistics, ordinal logistic regression with stepwise AIC selection, and one-sample proportion tests. FGD transcripts were analysed using modified framework analysis. Findings: Among 310 participants (102 Survey A; 208 Survey B), 83% (n=256) favoured LAIs over standard oral TB treatment. Compared with six months of daily oral treatment, 69% preferred a three-month regimen comprising one month of daily oral treatment followed by four injections per monthly visit for two months, while 80% preferred the corresponding regimen with two injections per visit. For prevention, 79% preferred a single injection over one month of oral treatment. In Survey B, interest varied according to lived TB experience, with FGDs suggesting that previous negative experiences with injectables may have contributed to this variation. Conclusion: Interest in LAIs for TB treatment and prevention was high, but lower among participants with lived TB experience. Product development and implementation should address concerns about injectables and side effects while preserving patient choice and agency.
ER -